Literature DB >> 7507055

Etiology of benign prostatic hyperplasia.

J T Isaacs1.   

Abstract

The natural history of benign prostatic hyperplasia (BPH) involves two phases. The first, or pathologic phase, is composed of two stages, microscopic and macroscopic, neither of which produces symptomatic clinical dysuria. Nearly all men throughout the world eventually develop microscopic BPH if they live long enough. In only about 50% of men, however, does microscopic BPH grow to produce a macroscopic enlargement of the gland, suggesting that additional factors are required for BPH progression. The second, or clinical, phase of BPH involves the progression of pathologic BPH to its clinical form, in which the patient develops symptomatic dysuria. Again, only about one half of the men with macroscopic BPH progress to clinical BPH. Although macroscopic enlargement of the prostate is necessary for the development of clinical BPH, it is usually not sufficient by itself for the progression to clinical BPH. Additional factors are required (e.g., prostatitis, vascular infarct, tensile strength of the glandular capsule). Successful treatment does not, therefore, require the prevention of pathologic BPH; instead, what is needed is a therapy to prevent or reverse the progression to clinical disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507055     DOI: 10.1159/000475324

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

1.  ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma.

Authors:  Natalie Sampson; Rafal Koziel; Christoph Zenzmaier; Lukas Bubendorf; Eugen Plas; Pidder Jansen-Dürr; Peter Berger
Journal:  Mol Endocrinol       Date:  2011-01-27

2.  Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.

Authors:  R Montironi; M Valli; G Fabris
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

3.  Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.

Authors:  S Dutkiewicz
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 4.  The effect of diet on BPH, LUTS and ED.

Authors:  Mahmoud ElJalby; Dominique Thomas; Dean Elterman; Bilal Chughtai
Journal:  World J Urol       Date:  2018-11-23       Impact factor: 4.226

Review 5.  [Etiology and pathophysiology of benign prostate hyperplasia].

Authors:  A Roosen; C Gratzke; A Herrlemann; G Magistro; F Strittmatter; P Weinhold; S Tritschler; C G Stief
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

Review 6.  The functional role of reactive stroma in benign prostatic hyperplasia.

Authors:  Isaiah G Schauer; David R Rowley
Journal:  Differentiation       Date:  2011-06-12       Impact factor: 3.880

7.  Bawu decoction () ameliorates benign prostatic hyperplasia in rats.

Authors:  Ji-Hwan Eom; Se-Yun Cheon; Kyung-Sook Chung; Myung-Dong Kim; Hyo-Jin An
Journal:  Chin J Integr Med       Date:  2016-11-12       Impact factor: 1.978

8.  Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Zongwei Wang; Mark G Vangel; Chin-Lee Wu; Shahin Tabatabaei; Aria F Olumi
Journal:  J Urol       Date:  2015-04-25       Impact factor: 7.450

9.  Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Authors:  Ferenc G Rick; Andrew Abi-Chaker; Luca Szalontay; Roberto Perez; Miklos Jaszberenyi; Arumugam R Jayakumar; Nagarajarao Shamaladevi; Karoly Szepeshazi; Irving Vidaurre; Gabor Halmos; Awtar Krishan; Norman L Block; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

Review 10.  [Pathophysiology and therapy of benign prostatic hyperplasia].

Authors:  Natalie Sampson; Stephan Madersbacher; Peter Berger
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.